Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ATRA Atara Biotherapeutics
5.170-0.290-5.31%
Close
02/03 16:00 ET
5.1700.0000.00%
Post Mkt Price 02/03 16:02 ET
High
5.380
Open
5.270
Turnover
4.09M
Low
5.165
Pre Close
5.460
Volume
783.07K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--$ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platf
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of "Hold" by Analysts
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) has received an average rating of "Hold" from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo
Assenagon Asset Management S.A. Decreases Stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Assenagon Asset Management S.A. reduced its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 0.9% in the third quarter, according to the company in its most recent filing with t
Atara Biotherapeutics (NASDAQ:ATRA) Research Coverage Started at EF Hutton Acquisition Co. I
EF Hutton Acquisition Co. I assumed coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) in a report issued on Thursday, Benzinga reports. The brokerage issued a buy rating and a $2
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
UpgradesFor Algonquin Power & Utilities Corp (NYSE:AQN), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Algonquin Power showed an EPS of $0.11, compared
Atara Biotherapeutics Price Target Announced at $25.00/Share by EF Hutton
Atara Biotherapeutics Price Target Announced at $25.00/Share by EF Hutton
EF Hutton Initiates Coverage On Atara Biotherapeutics With Buy Rating, Announces Price Target of $25
EF Hutton analyst Tony Butler initiates coverage on Atara Biotherapeutics (NASDAQ:ATRA) with a Buy rating and announces Price Target of $25.
Atara Biotherapeutics Initiated With a Buy at EF Hutton
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Company Overview
More
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
CEO： Dr. Pascal Touchon
Market： NASDAQ
Listing Date： 10/16/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet